<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gauthier A</submitter><funding>Agence Nationale de la Recherche</funding><pagination>1141-1150</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8108418</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8(5)</volume><pubmed_abstract>We compared Simoa&lt;sup>TM&lt;/sup> and Ella&lt;sup>TM&lt;/sup> immunoassays to assess serum neurofilament-light chain levels in 203 multiple sclerosis patients from the OFSEP HD study. There was a strong correlation (ρ = 0.86, p &lt; 0.0001) between both platforms. The Ella&lt;sup>TM&lt;/sup> instrument overestimated values by 17%, but as the data were linear (p = 0.57), it was possible to apply a correction factor to Ella&lt;sup>TM&lt;/sup> results. As for Simoa&lt;sup>TM&lt;/sup> , serum neurofilament-light chain levels measured by Ella&lt;sup>TM&lt;/sup> were correlated with age and EDSS and were significantly higher in active multiple sclerosis, suggesting that these assays are equivalent and can be used in routine clinical practice.</pubmed_abstract><journal>Annals of clinical and translational neurology</journal><pubmed_title>Comparison of Simoa&lt;sup>TM&lt;/sup> and Ella&lt;sup>TM&lt;/sup> to assess serum neurofilament-light chain in multiple sclerosis.</pubmed_title><pmcid>PMC8108418</pmcid><funding_grant_id>ANR‐10‐COHO‐002</funding_grant_id><pubmed_authors>Perret M</pubmed_authors><pubmed_authors>Castelnovo G</pubmed_authors><pubmed_authors>Debouverie M</pubmed_authors><pubmed_authors>Lebrun-Frenay C</pubmed_authors><pubmed_authors>Brocard G</pubmed_authors><pubmed_authors>Berger E</pubmed_authors><pubmed_authors>Gout O</pubmed_authors><pubmed_authors>Moreau T</pubmed_authors><pubmed_authors>Gauthier A</pubmed_authors><pubmed_authors>Casey R</pubmed_authors><pubmed_authors>De Seze J</pubmed_authors><pubmed_authors>OFSEP Investigators</pubmed_authors><pubmed_authors>Casez O</pubmed_authors><pubmed_authors>Clavelou P</pubmed_authors><pubmed_authors>Trouillet-Assant S</pubmed_authors><pubmed_authors>Vukusic S</pubmed_authors><pubmed_authors>Viel S</pubmed_authors><pubmed_authors>Laplaud DA</pubmed_authors><pubmed_authors>Zephir H</pubmed_authors><pubmed_authors>Laurent-Chabalier S</pubmed_authors><pubmed_authors>Edan G</pubmed_authors><pubmed_authors>Ruet A</pubmed_authors><pubmed_authors>Thouvenot E</pubmed_authors><pubmed_authors>Lombard C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comparison of Simoa&lt;sup>TM&lt;/sup> and Ella&lt;sup>TM&lt;/sup> to assess serum neurofilament-light chain in multiple sclerosis.</name><description>We compared Simoa&lt;sup>TM&lt;/sup> and Ella&lt;sup>TM&lt;/sup> immunoassays to assess serum neurofilament-light chain levels in 203 multiple sclerosis patients from the OFSEP HD study. There was a strong correlation (ρ = 0.86, p &lt; 0.0001) between both platforms. The Ella&lt;sup>TM&lt;/sup> instrument overestimated values by 17%, but as the data were linear (p = 0.57), it was possible to apply a correction factor to Ella&lt;sup>TM&lt;/sup> results. As for Simoa&lt;sup>TM&lt;/sup> , serum neurofilament-light chain levels measured by Ella&lt;sup>TM&lt;/sup> were correlated with age and EDSS and were significantly higher in active multiple sclerosis, suggesting that these assays are equivalent and can be used in routine clinical practice.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 May</publication><modification>2025-04-06T23:53:35.315Z</modification><creation>2025-04-04T14:55:25.659Z</creation></dates><accession>S-EPMC8108418</accession><cross_references><pubmed>33830650</pubmed><doi>10.1002/acn3.51355</doi></cross_references></HashMap>